Details for Patent: 6,610,883

Title:	Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
Abstract:	Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, pyrrole, and polyenoic acid derivatives including carbocyclic polyenoic acids. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
Inventor(s):	Boehm; Marcus F. (San Diego, CA), Heyman; Richard A. (Encinitas, CA), Zhi; Lin (San Diego, CA), Hwang; Chan Kou (Jack) (San Diego, CA), White; Steve (San Diego, CA), Nadzan; Alex (San Diego, CA)
Assignee:	Ligand Pharmaceuticals, Inc. (San Diego, CA)
Filing Date:	Jul 13, 1998
Application Number:	09/115,615
Claims:	1. A compound having the formula: ##STR32## wherein R.sub.1 and R.sub.2, each independently, represent hydrogen or lower alkyl or acyl having 1-4 carbon atoms; Y represents C, O, S, N, CHOH, CO, SO, SO.sub.2, or a pharmaceutically acceptable salt; R.sub.3 represents hydrogen or lower alkyl having 1-4 carbon atoms where Y is C or N; R.sub.4 represents hydrogen or lower alkyl having 1-4 carbon atoms where Y is C, but R.sub.4 does not exist if Y is N, and neither R.sub.3 or R.sub.4 exist if Y is S, O, CHOH, CO, SO, or SO.sub.2 ; R' and R" represent hydrogen, lower alkyl or acyl having 1-4 carbon atoms, OH, alkoxy having 1-4 carbon atoms, thiol or thio ether, or amino, or R' or R" taken together form an oxo (keto), methano, thioketo, HO--N.dbd., NC--N.dbd., (R.sub.7 R.sub.8)N--N.dbd., R.sub.17 O--N.dbd., R.sub.17 N.dbd., epoxy, cyclopropyl, or cycloalkyl group and wherein the epoxy, cyclopropyl, and cycloalkyl groups can be substituted with lower alkyl having 1-4 carbons or halogen; R.sub.7 represents hydrogen or a lower alkyl having 1-6 carbons; R.sub.8 represents hydrogen or a lower alkyl having 1-6 carbons; R.sub.9 represents a lower alkyl having 1-4 carbons, phenyl, aromatic alkyl, or q-hydroxyphenyl, q-bromophenyl, q-chlorophenyl, q-florophenyl, or q-iodophenyl, where q=2-4; R.sub.15 represents a lower or branched alkyl having 1-12 carbons, and can be methyl only if R.sub.16 is a halogen or a lower alkyl having 1-8 carbons; R.sub.16 represents hydrogen, a lower alkyl having 1-8 carbons, or halogen, or R.sub.15 and R.sub.16 taken together form a phenyl, cyclohexyl, or cyclopentyl ring or one of the following: ##STR33## R.sub.17 represents hydrogen, lower alkyl having 1-8 carbons, alkenyl (including halogen, acyl, OR.sub.7 and SR.sub.7 substituted alkenes), R.sub.9, alkyl carboxylic acid (including halogen, acyl, OR.sub.7 and SR.sub.7 substituted alkyls), alkenyl carboxylic acid (including halogen, acyl, OR.sub.7 and SR.sub.7 substituted alkenes), alkyl amines (including halogen, acyl, OR.sub.7 and SR.sub.7 substituted alkyls), and alkenyl amines (including halogen, acryl, OR.sub.7 and SR.sub.7 substituted alkenes); R.sub.18 represents hydrogen, a lower alkyl having 1-4 carbons, halogen, nitro, OR.sub.7, SR.sub.7, NR.sub.7 R.sub.8, or (CF).sub.n CF.sub.3 ; R.sub.19 represents hydrogen, lower alkyl having 1-8 carbons, halogen, OR.sub.7 ; SR.sub.7, or (CF).sub.n CF.sub.3 ; V is COOH, tetrazole, PO.sub.3 H, SO.sub.3 H, CHO, CH.sub.2 OH, CONH.sub.2, COSH, COOR.sub.9, COSR.sub.9, CONHR.sub.9, or COOW where and where W is a pharmaceutically acceptable salt; Z, Z', Z", and Z'", each independently, represent C, S, O, N, or a pharmaceutically acceptable salt, but is not O or S if attached by a double bond to another such Z or if attached to another such Z which is O or S, and is not N if attached by a single bond to another such Z which is N; n=0-3; and the dashed lines in the structures depict optional double bonds. 2. A compound of claim 1 wherein said compound selectively activates Retinoid X Receptors in preference to Retinoic Acid Receptors. 3. The compound of claim 2 wherein said compound is at least three-fold more potent an activator of Retinoid X Receptors than of Retinoic Acid Receptors. 4. A compound selected from the group consisting of 3-methyl-7-ethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2E,4E,6Z,8E-nonatet ranoic acid, 3-methyl-7-propyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2E,4E,6Z,8E-nonatet ranoic acid, 3-methyl-7-isopropyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2E,4E,6Z,8E-nona tetranoic acid, 3,6,7-trimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2E,4e,6Z,8e-nonatetra noic acid, 3-methyl-7-t-butyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2E,4E,6Z,8E-nonate tranoic acid, 3-methyl-5-{2-[2-(2,6,6-trimethylcyclohexen-1-yl)ethenyl]phenyl}-2E,4E-pent adienoic acid, 3-methyl-5-{2-[2-(2,6,6-trimethylcyclohexen-1-yl)ethenyl]cyclohexyl}-2E,4E- pentadienoic acid, (2E,4E)-3-methyl-6-{1-[2,6,6-trimethyl-1-cyclohexenyl)ethenyl]cyclopropyl}- 2,4-hexadienoic acid, (2E,4E,6Z)-7-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)-3,8-dimeth yl-nona-2,4,6-trienoic acid, and (2E,4E,6Z)-7-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-3-methyl -octa-2,4,6-trienoic acid. 5. A pharmaceutical composition comprising in a pharmaceutically acceptable vehicle suitable for enteral, parenteral, or topical administration, one or more compound of claim 1. 6. A method for modulating a process mediated by one or more Retinoid X Receptors, said method comprising causing said process to be conducted in the presence of at least one compound as set forth in claim 1. 7. A method according to claim 6 wherein said Retinoid X Receptor is Retinoid X Receptor-alpha, Retinoid X Receptor-beta, or Retinoid X Receptor-gamma. 8. A method according to claim 6 wherein said process is the in vivo modulation of lipid metabolism, in vivo modulation of skin-related processes, in vivo modulation of malignant cell development, in vivo modulation of premalignant lesions; or in vivo modulation of programmed cell death. 9. A method according to claim 6 wherein said process is in vivo or in vitro cellular growth and differentiation, or in vivo limb morphogenesis. 10. A method for modulating a process mediated by one or more Retinoid X Receptors, said method comprising administering to a mammalian subject an amount, effective to modulate said process mediated by said one or more Retinoid X Receptors, of one or more compound of claim 1. 11. A method for modulating a process mediated by one or more Retinoid X Receptors, said method comprising administering to a mammalian subject an amount, effective to modulate said process mediated by said one or more Retinoid X Receptors, of one or more compound of claim 3. 12. A method for treating a mammalian subject requiring Retinoid X Receptor therapy comprising administering to such subject a pharmaceutically effective amount of one or more compounds as set forth in claim 1. 13. A method for treating a mammalian subject requiring Retinoid X Receptor therapy comprising administering to such subject a pharmaceutically effective amount of one or more compounds as set forth in claim 3. 14. A method for increasing plasma concentrations of high density lipoprotein in a mammalian subject comprising administering to such subject a pharmaceutically effective amount of one or more compounds as set forth in claim 1. 15. A method for modulating a process mediated by intracellular receptors, said method comprising causing said process to be conducted in the presence of a composition comprising a first compound as set forth in claim 1 which selectively activates Retinoid X Receptors in preference to Retinoid Acid Receptors, in combination with a second compound which activates one or more intracellular receptors other than Retinoid X Receptors, and wherein the physiological effect in mammals produced by said composition at a given concentration is greater than the additive effect achieved by utilizing each said compound alone at said concentration. 16. A method for modulating a process mediated by one or more Retinoid X Receptors, said method comprising causing said process to be conducted in the presence of one or more compounds of claim 4. 17. A method for treating a mammalian subject requiring Retinoid X Receptor therapy comprising administering to such subject a pharmaceutically effective amount of one or more compounds of claim 4.